AVITA Medical, Inc. reported a total revenue of $71.6 million for the fiscal year ending December 31, 2025, marking an 11% increase from $64.3 million in 2024. The growth was primarily attributed to deeper market penetration and the introduction of new products, including the RECELL GO and Cohealyx. Despite the revenue increase, the company recorded a net loss of $48.6 million, a reduction from the previous year's loss of $61.8 million, driven by higher gross profit and lower operating expenses.
The company's gross profit margin decreased to 82.1% from 85.8% in the prior year, largely due to a shift in product mix and increased inventory reserves. Operating expenses fell by 9% to $101.4 million, with significant reductions in sales and marketing expenses, which decreased by 9% to $53.1 million, and general and administrative expenses, which dropped 18% to $27.3 million. Research and development expenses saw a slight increase of 2% to $20.8 million.
Strategically, AVITA Medical has expanded its product offerings and market reach. In January 2024, the company entered into a multi-year distribution agreement with Stedical Scientific, Inc. for PermeaDerm, and in July 2024, it secured a similar agreement with Regenity for Cohealyx. The RECELL GO mini, designed for smaller wounds, received FDA approval in December 2024, with commercial rollout beginning in early 2025. The company is also pursuing international expansion, having received CE Mark approval for RECELL GO in September 2025.
Operationally, AVITA Medical employed approximately 226 individuals as of December 31, 2025, with a focus on enhancing its sales and marketing capabilities. The company aims to increase its market share in U.S. burn centers and expand the adoption of its products in trauma and surgical settings. Looking ahead, AVITA Medical anticipates continued revenue growth, driven by its strategic initiatives and product innovations, while also managing its debt obligations under a new credit facility established in January 2026.
About AVITA Medical, Inc.
AVITA Medical develops and commercializes advanced acute wound care solutions centered on its patented RECELL technology, which creates autologous skin cell suspensions to accelerate healing of burns, full-thickness skin defects, and vitiligo. The company’s product portfolio includes RECELL devices and complementary wound care matrices like PermeaDerm and Cohealyx. Serving burn and trauma centers primarily in the U.S. and select international markets, AVITA leverages proprietary technology, regulatory approvals, and clinical evidence to improve patient outcomes and reduce treatment costs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.